human
cytomegaloviru
hcmv
herpesviru
ubiquit
distribut
pathogen
caus
sever
diseas
immunosuppress
patient
infect
newborn
effort
underway
prepar
effect
subunit
vaccin
therapi
includ
antivir
antibodi
howev
current
vaccin
effort
hamper
lack
inform
protect
immun
respons
hcmv
character
bcell
respons
healthi
infect
individu
could
aid
design
optim
vaccin
therapeut
antibodi
address
problem
determin
first
time
bcell
repertoir
glycoprotein
b
gb
hcmv
differ
healthi
hcmv
seroposit
individu
unbias
fashion
hcmv
gb
repres
domin
viral
antigen
determin
induct
neutral
antibodi
infect
also
compon
sever
experiment
hcmv
vaccin
current
test
human
find
reveal
vast
major
gbspecif
antibodi
secret
bcell
clone
viru
neutral
activ
neutral
antibodi
found
bind
epitop
locat
within
previous
character
antigen
domain
ad
gb
map
target
structur
neutral
antibodi
gener
model
hcmv
gb
use
identifi
surfac
expos
protein
domain
two
protein
domain
found
target
major
neutral
antibodi
domain
locat
amino
acid
aa
gb
domain
ii
discontinu
domain
built
residu
analysi
larger
panel
human
sera
hcmv
seroposit
individu
reveal
posit
rate
domain
domain
ii
respect
accord
previou
nomenclatur
domain
design
dom
ii
dom
respect
collect
data
contribut
optim
vaccin
design
develop
antibodi
effect
passiv
immun
human
cytomegaloviru
hcmv
import
ubiquit
occur
human
pathogen
immunocompromis
host
viru
caus
sever
diseas
transplant
recipi
larg
part
world
hcmv
also
common
viral
infect
acquir
utero
usa
europ
estim
live
born
infant
infect
hcmv
congenit
hcmv
infect
lead
caus
sensorineur
hear
loss
children
lead
infecti
caus
central
nervou
system
damag
children
consequ
import
congenit
hcmv
infect
public
health
institut
medicin
nation
academi
scienc
usa
rank
develop
hcmv
vaccin
top
prioriti
success
antivir
vaccin
induct
effici
antibodi
respons
crucial
success
vaccin
importantli
effect
antihcmv
vaccin
need
protect
vaccin
hcmv
infectiondiseas
well
case
pregnant
women
develop
fetu
transfer
protect
matern
antibodi
fetu
critic
respect
studi
passiv
transfer
immunoglobulin
pregnant
mother
support
role
antibodi
reduc
risk
congenit
infect
also
natur
acquir
matern
immun
contribut
prevent
congenit
hcmv
infect
although
correl
protect
hcmv
infect
poorli
understood
predict
humor
immun
respons
envelop
glycoprotein
particularli
import
sinc
antibodi
direct
antigen
neutral
viru
infect
directli
andor
induc
immunoglobulin
fcreceptor
mediat
effector
function
antibodi
depend
cytotox
andor
complement
mediat
effect
lead
elimin
infect
cell
hcmv
highli
complex
viru
harbor
differ
glycoprotein
envelop
respect
induct
neutral
antibodi
natur
infect
glycoprotein
g
b
domin
addit
antigen
gmgn
complex
ghgl
complex
also
identifi
highli
immunogen
antibodi
direct
gb
detect
natur
infect
individu
moreov
major
fraction
neutral
antibodi
human
sera
seem
direct
gb
overal
neutral
capac
sera
hcmvseroposit
donor
correl
antigb
antibodi
titer
addit
antigb
antibodi
effect
prevent
celltocel
spread
guinea
pig
cmv
model
immun
gb
dna
vaccin
confer
protect
infect
recent
studi
protect
brain
patholog
murin
cytomegaloviru
mcmv
infect
mice
accomplish
passiv
transfer
gbspecif
monoclon
antibodi
mab
thu
gb
attract
antigen
inclus
human
vaccin
part
number
experiment
vaccin
fact
recent
phase
trial
use
recombin
gb
vaccin
shown
signific
protect
infect
howev
spectrum
antigb
antibodi
develop
infect
remain
poorli
defin
hcmv
gb
essenti
viral
protein
involv
earli
event
infect
shown
bind
varieti
cell
surfac
molecul
heparan
sulfat
proteoglycan
integrin
heterodim
plateletderiv
growth
factora
receptor
addit
hcmv
gb
shown
mediat
fusion
viral
cellular
membran
protein
essenti
viral
entri
celltocel
spread
virion
attach
assembl
egress
three
antigen
domain
ad
describ
previous
consist
approxim
posit
gb
hcmv
strain
immunodomin
region
gb
sinc
nearli
sera
hcmvinfect
individu
recogn
antibodi
bind
viru
neutral
capac
indic
fact
number
human
mab
isol
show
variou
degre
neutral
activ
polyclon
antibodi
purifi
human
serum
incap
complet
neutral
hcmv
even
high
concentr
indic
bound
antibodi
wide
differ
neutral
activ
suggest
competit
bind
neutral
nonneutr
antibodi
may
repres
mechan
evad
effici
neutral
cell
free
viru
locat
extrem
amino
terminu
protein
consist
least
two
distinct
site
aa
gb
site
common
hcmv
strain
induc
neutral
antibodi
wherea
aa
sequenc
site
ii
differ
strain
recogn
strain
specif
antibodi
incap
neutral
vitro
overal
immunogen
lower
sinc
human
sera
hcmvinfect
donor
antibodi
determin
addit
linear
aa
sequenc
recogn
gbspecif
antibodi
human
sera
includ
epitop
intraluminalintravir
part
molecul
howev
antibodi
bind
determin
nonneutr
expect
local
within
molecul
addit
protein
domain
bound
murin
mab
identifi
whether
region
relev
context
antibodi
respons
natur
infect
unknown
gbspecif
human
monoclon
antibodi
bind
site
identifi
react
either
overal
signific
gap
knowledg
antibodi
epitop
gb
given
size
gb
protein
seem
highli
like
addit
antigen
domain
exist
gb
defin
site
provid
antigen
map
import
protein
also
help
monitor
respons
vaccin
product
antibodi
bind
profil
similar
natur
infect
comprehens
analyz
human
antibodi
repertoir
gb
develop
infect
end
isol
gbspecif
memori
b
cell
differ
healthi
hcmvseroposit
donor
activ
cell
clonal
level
immunoglobulin
product
produc
antibodi
test
reactiv
gb
part
thereof
vitro
neutral
assay
result
reveal
antigb
antibodi
produc
infect
fail
neutral
cellfre
viru
addit
perhap
importantli
find
vast
major
antigb
antibodi
potent
neutral
capac
recogn
two
protein
domain
identifi
previous
target
site
antibodi
repertoir
gb
domin
antibodi
neutral
viru
bind
unknown
protein
domain
intend
comprehens
analyz
human
igg
antigb
memori
blymphocyt
repertoir
establish
healthi
hcmv
infect
individu
term
epitop
specif
well
neutral
capac
end
use
complet
extravir
part
gb
use
vaccin
trial
sort
igg
posit
memori
blymphocyt
bind
fluorochromelabel
gb
flow
cytometri
fig
first
set
experi
analyz
possibl
identifi
develop
antibodi
major
defens
mechan
virus
understand
repertoir
antivir
antibodi
induc
infect
necessari
prerequisit
defin
protect
activ
antivir
antibodi
respons
isol
antigen
specif
memori
b
cell
subsequ
stimul
antibodi
produc
cell
provid
power
tool
studi
antibodi
repertoir
infect
individu
use
approach
analyz
antibodi
repertoir
glycoprotein
b
gb
human
cytomegaloviru
hcmv
major
antigen
induct
antivir
antibodi
infect
constitu
experiment
vaccin
human
find
differ
infect
individu
vast
major
gbspecif
b
cell
produc
antibodi
neutral
free
viru
antibodi
antivir
capac
target
two
domain
gb
previous
identifi
identif
new
antigen
domain
possibl
aid
molecular
model
hcmv
gb
result
use
vaccin
develop
sinc
comparison
immun
respons
natur
infect
induc
vaccin
readili
accomplish
moreov
neutral
human
monoclon
antibodi
could
constitut
power
therapeut
combat
infect
popul
risk
hcmv
diseas
gbspecif
memori
b
cell
seroposit
individu
frequenc
gbbind
iggposit
memori
b
cell
among
iggposit
memori
b
cell
rang
rang
frequenc
igg
memori
blymphocyt
viral
antigen
fig
among
hcmv
seroneg
individu
gbbind
memori
b
cell
detect
consider
lower
frequenc
cell
might
bind
gb
unspecif
may
repres
part
natur
antibodi
repertoir
sort
gbbind
b
cell
activ
immort
clonal
level
vitro
cultur
system
use
cpg
oligonucleotid
ebv
among
clonal
cultur
igg
secret
mean
cultur
show
igg
bind
gb
elisa
substanti
high
degre
specif
cell
sort
process
data
shown
seven
donor
select
analysi
antigb
antibodi
titer
compar
group
fig
neutral
titer
vari
significantli
uncommon
hcmvinfect
individu
fig
donor
abl
analyz
total
clonal
igg
gbbind
cultur
supernat
epitop
specif
toward
wellknown
antigen
domain
well
neutral
capac
hcmv
fibroblast
respect
bind
gb
protein
domain
found
high
frequenc
antibodi
bind
epitop
mean
individu
correl
earlier
find
gbspecif
igg
sera
might
direct
epitop
tabl
interestingli
antibodi
abl
neutral
hcmv
vitro
mean
rang
tabl
frequenc
clone
produc
igg
low
tabl
individu
abl
retriev
memori
b
cell
correl
earlier
data
specif
found
approxim
hcmv
infect
individu
none
rare
antibodi
neutral
vitro
high
frequenc
clone
individu
react
either
rang
tabl
importantli
among
antibodi
signific
number
abl
neutral
hcmv
vitro
clone
tabl
summari
neutral
capac
gbspecif
bcell
supernat
donor
abl
isol
b
cell
secret
neutral
antibodi
shown
fig
conclud
analysi
memori
bcell
repertoir
gb
domin
antibodi
neutral
viru
neutral
antibodi
bind
far
unknown
antigen
site
neutral
human
monoclon
antibodi
bind
region
residu
gb
next
attempt
map
target
site
antibodi
react
known
antigen
site
gb
obtain
consist
suppli
mab
iggen
select
bcell
clone
secret
neutral
antibodi
unreact
clone
express
recombin
system
molecul
tabl
choos
subtyp
sinc
select
bcell
clone
secret
wherea
secret
recombin
antibodi
show
compar
neutral
activ
bcell
supernat
test
fibroblast
target
cell
indic
fcpart
igg
significantli
contribut
vitro
neutral
activ
antibodi
fig
neutral
achiev
concentr
mgml
tabl
importantli
recombin
antibodi
also
abl
neutral
viru
endotheli
epitheli
dendrit
cell
compar
activ
repres
result
group
mab
see
next
paragraph
endotheli
cell
group
b
mab
epitheli
cell
shown
fig
data
mab
summar
tabl
fact
test
antibodi
reactiv
western
blot
analys
use
extracellular
hcmv
particl
antigen
indic
intact
threedimension
protein
conform
crucial
bind
data
shown
therefor
use
indirect
immunofluoresc
transient
express
fragment
gb
cell
obtain
inform
bind
site
mab
two
distinct
reactiv
pattern
observ
mab
group
group
b
fig
full
length
gb
fragment
short
gb
reactiv
entir
set
tabl
epitop
specif
neutral
activ
igg
hcmvgb
specif
antibodi
fig
group
mab
gb
residu
suffici
bind
wherea
group
b
antibodi
larger
fragment
gb
compris
residu
requir
bind
indic
gb
region
aa
harbor
least
two
distinguish
antibodi
target
site
gener
structur
model
gb
reveal
two
globular
protein
domain
within
antibodi
bind
region
gb
order
obtain
inform
potenti
structur
domain
gb
region
aa
gener
three
dimension
model
trimer
conform
ectodomain
hcmv
gb
strain
base
crystal
structur
gb
fig
accord
model
overal
structur
hcmv
gb
monom
organ
subunit
trimer
highli
similar
gb
expect
degre
sequenc
similar
gb
human
herpesvirus
ident
similar
gb
hcmv
strain
gb
individu
domain
v
previous
defin
base
gb
structur
clearli
identifi
homolog
model
hcmv
gb
respect
potenti
antibodi
bind
structur
protein
domain
dom
ii
particular
interest
sinc
locat
within
aa
gb
dom
ile
thr
constitut
part
trimer
interfac
locat
proxim
membran
potenti
contain
fusion
domain
discontinu
dom
ii
compos
two
separ
segment
compris
residu
leu
asn
cy
ser
fig
either
domain
contain
singl
disulfid
bond
help
stabil
conform
respect
protein
domain
investig
dom
dom
ii
antibodi
bind
express
plasmid
construct
allow
synthesi
either
domain
eukaryot
cell
case
clone
strategi
involv
attach
ha
epitop
tag
amino
terminu
respect
peptid
order
facilit
detect
dom
compris
aa
gb
dom
iispecif
peptid
consist
gbspecif
residu
join
aa
ilealaglysergli
synthet
linker
sequenc
follow
transient
express
peptid
cell
antibodi
bind
analyz
indirect
immunofluoresc
four
antibodi
group
reactiv
dom
ispecif
peptid
wherea
group
b
mab
recogn
dom
ii
fig
tabl
crystal
structur
gb
well
model
hcmv
gb
predict
dom
dom
ii
discontinu
sequenc
stretch
essenti
format
either
domain
shorter
protein
fragment
would
expect
fold
correctli
test
assumpt
express
dom
ii
variant
five
amino
acid
delet
carboxylterminu
observ
complet
loss
bind
group
aspecif
antibodi
likewis
continu
part
dom
residu
show
antibodi
bind
capac
data
shown
thu
resolut
antibodi
epitop
possibl
gener
point
mutant
dom
dom
ii
respect
identifi
dom
dom
ii
new
target
neutral
antibodi
retest
clonal
antibodi
supernat
individu
obtain
inform
overal
frequenc
dom
iand
dom
iispecif
antibodi
hcmv
infect
individu
shown
tabl
frequenc
dom
dom
ii
specif
memori
b
cell
variabl
among
differ
donor
case
consider
lower
compar
b
cell
summari
repertoir
analysi
reveal
antigb
igg
antibodi
deriv
memori
b
cell
nonneutr
among
antibodi
neutral
hcmv
vitro
antibodi
react
two
previous
uncharacter
region
gb
protein
addit
complement
influenc
neutral
capac
recombin
antibodi
moreov
select
set
n
nonneutr
antibodi
direct
differ
antigen
domain
gb
test
concentr
mgml
presenc
complement
observ
signific
increas
neutral
capac
agreement
previou
report
gbspecif
human
mab
data
shown
howev
complet
rule
moder
enhanc
effect
complement
antibodi
especi
subtyp
dom
dom
ii
mab
function
postadorpt
step
infect
gb
postul
involv
receptor
bind
hcmv
entri
therefor
analyz
stage
infect
mab
exert
action
assay
influenc
attach
virusantibodi
mixtur
ad
target
cell
number
hcmv
dna
copi
attach
cell
determin
quantit
real
time
pcr
neither
dom
inor
dom
iispecif
antibodi
inhibit
attach
virion
indic
mab
block
receptor
bind
hcmv
fig
accord
previou
report
heparin
almost
complet
prevent
viru
attach
wherea
antibodi
effect
viru
bind
slight
increas
bound
viru
presenc
antibodi
compar
control
might
reflect
deposit
antibodyviru
aggreg
surfac
cell
also
determin
activ
mab
toward
viru
alreadi
adsorb
cell
end
viru
preadsorb
cell
h
antibodi
ad
dom
iand
dom
iispecif
antibodi
capabl
neutral
hcmv
postadsorpt
step
wherea
nonneutr
antibodi
effect
fig
higher
antibodi
concentr
requir
complet
neutral
adsorb
viru
explain
need
block
fusion
alreadi
adsorb
viru
particl
competit
bind
neutral
nonneutr
human
mab
describ
gb
test
whether
similar
phenomenon
occur
dom
ior
dom
iispecif
neutral
antibodi
total
nonneutr
mab
direct
differ
antigen
region
gb
analyz
neutral
assay
competit
dom
ior
dom
iispecif
mab
case
observ
reduct
neutral
capac
addit
nonneutr
mab
result
repres
analysi
shown
fig
although
data
indic
reduct
neutral
activ
compet
nonneutr
mab
common
dom
iand
dom
iispecif
antibodi
difficult
assess
relev
find
situat
human
sera
antibodi
clearli
shown
sum
antibodi
present
human
sera
capabl
complet
neutral
infecti
viru
indic
nonneutr
antibodi
constitut
signific
fraction
entir
igg
fraction
obtain
inform
neutral
capac
dom
iispecif
antibodi
human
sera
purifi
dom
ii
gst
fusion
protein
follow
express
e
coli
fig
bacteri
deriv
peptid
retain
capac
bind
group
b
mab
affin
mab
similar
gb
dom
ii
fig
circular
dichroism
spectra
indic
homogen
threedimension
structur
fig
use
protein
polyclon
dom
iispecif
antibodi
affinitypurifi
pool
human
sera
fig
affinitypurifi
igg
prepar
test
neutral
assay
neutral
input
viral
infect
achiev
igg
concentr
approxim
mgml
within
concentr
rang
dom
iispecif
mab
fig
summari
data
provid
evid
gb
dom
ii
repres
immunogen
domain
gb
also
antibodi
bind
gener
potent
neutral
capac
similar
experi
use
dom
could
carri
sinc
dom
domain
fold
correctli
prokaryot
express
thu
antigen
affin
purif
antibodi
could
gener
previou
analys
human
sera
recognit
gb
domain
reveal
differenti
rate
antibodi
reactiv
individu
antigen
domain
wherea
almost
infect
individu
develop
antibodi
show
reactiv
obtain
inform
frequenc
recognit
dom
dom
ii
determin
antibodi
reactiv
domain
larger
serum
panel
hcmv
infect
individu
compar
known
antigen
domain
total
randomli
select
sera
hcmv
seroposit
individu
determin
commerci
avail
elisa
test
analyz
ten
sera
hcmv
neg
donor
serv
control
within
serum
panel
hcmvseroposit
individu
reactiv
gb
underscor
antigen
protein
fig
accord
previou
observ
posit
reaction
also
sera
contain
antibodi
dom
recogn
wherea
specimen
react
dom
ii
thu
dom
dom
ii
repres
antigen
domain
gb
induc
antibodi
high
frequenc
infect
sake
consist
nomenclatur
gb
antigen
domain
design
dom
ii
dom
use
recombin
gb
analyz
antibodi
repertoir
deriv
activ
memori
b
cell
healthi
hcmv
seroposit
individu
donor
select
hight
titer
antigb
neutral
antibodi
hcmv
order
obtain
unbias
result
result
reveal
number
new
find
respect
antigb
respons
human
vast
major
antigb
antibodi
show
antivir
activ
vitro
assay
among
seven
donor
test
comprehens
percentag
neutral
antibodi
among
gb
binder
rang
mean
previou
studi
use
adsorpt
antibodi
gb
note
individu
overal
neutral
capac
reduc
indic
case
nongb
specif
antibodi
major
compon
neutral
antibodi
respons
repertoir
analysi
viral
system
also
notic
excess
bind
versu
neutral
antibodi
time
specul
potenti
role
nonneutr
antibodi
infect
vivo
besid
irrelev
infect
nonneutr
antibodi
might
posit
neg
effect
effector
function
mediat
via
fcportion
antibodi
adcc
andor
complement
fixat
may
contribut
elimin
infect
cell
thu
could
lead
enhanc
clearanc
cell
mechan
oper
vivo
shown
differ
viral
system
includ
herpesvirus
hcmv
hand
infectionenhanc
effect
could
contribut
mechan
competit
nonneutr
antibodi
bind
neutral
epitop
enhanc
infect
fcreceptor
bear
cell
monocyt
one
major
target
cell
popul
hcmv
infect
vivo
wherea
antigb
mab
recogn
mammalian
cell
express
gb
aa
antigb
antibodi
reactiv
shorter
fragment
express
aa
indic
presenc
epitop
gb
aa
antibodi
neg
recognit
bacteri
fusion
protein
contain
aa
thu
locat
antibodi
bind
site
remain
unknown
possibl
residu
contain
addit
epitop
sinc
repres
fusion
peptid
howev
seem
unlik
plausibl
explan
find
region
aa
contain
addit
conform
epitop
form
bacteri
fusion
protein
previou
analys
shown
induc
multitud
antibodi
differ
bind
characterist
even
assay
bacteri
fusion
protein
synthet
peptid
thu
would
surpris
region
gb
contain
addit
epitop
present
nativ
protein
larg
fraction
antibodi
fall
categori
also
support
possibl
correspond
protein
region
gb
found
contain
pseudocontinu
epitop
support
interpret
howev
matter
underli
mechan
find
antibodi
bind
within
region
gb
nonneutr
antibodi
show
potent
vitro
neutral
activ
found
bind
two
previous
unknown
protein
domain
name
demonstr
donor
unlik
sampl
artifact
antigen
domain
also
indic
fact
randomli
select
serum
sampl
hcmvseroposit
donor
found
posit
rate
identifi
domain
strongli
antigen
structur
gb
compar
posit
rate
among
sera
hcmv
infect
individu
report
respect
confirm
current
analysi
distinct
differ
function
antivir
activ
domain
specif
antibodi
bound
viru
neutral
nonneutr
monoclon
antibodi
compet
bind
domain
affin
purifi
igg
fraction
pool
human
sera
shown
neutral
capac
exceed
indic
natur
infect
consider
proport
compet
nonneutr
antibodi
induc
incomplet
neutral
capac
polyclon
antibodi
suggest
provid
viru
effect
mechan
evad
humor
immun
respons
likewis
harbor
two
differ
antibodi
bind
site
bound
neutral
nonneutr
antibodi
respect
situat
seem
differ
almost
human
monoclon
antibodi
obtain
far
potent
viru
neutral
activ
moreov
affinitypurifi
polyclon
human
igg
fraction
neutral
titer
compar
monoclon
antibodi
neutral
low
nanomolar
rang
thu
seem
unlik
induc
signific
concentr
nonneutr
antibodi
compet
neutral
antibodi
bind
domain
whether
correl
also
hold
true
need
determin
studi
mab
prevent
viru
attach
fibroblast
indic
neither
type
antibodi
interfer
receptor
bind
hcmv
howev
capabl
neutral
infecti
viru
postadsorpt
step
case
shown
neutral
antigb
murin
mab
differ
effector
mechan
antibodi
bind
hsvgb
domain
iv
correspond
hcmv
gb
block
fusion
viral
cellular
membran
interfer
interact
gb
ghgl
second
constitu
minim
herpesvir
fusion
complex
murin
mab
specif
hsvgb
domain
ii
correspond
hcmv
gb
block
interact
gb
gh
gl
therebi
inhibit
fusion
whether
similar
effector
mechan
appli
hcmv
need
determin
studi
hcmv
isol
clinic
sampl
exhibit
extens
genet
variat
hcmv
reinfect
demonstr
occur
seroposit
individu
immunocompromis
host
develop
de
novo
humor
immun
respons
impair
reinfect
differ
hcmv
isol
might
result
clinic
symptom
due
unrestrict
replic
new
viru
strain
howev
inform
whether
reinfect
seroposit
individu
inevit
upon
contact
differ
hcmv
strain
whether
infect
host
develop
immun
respons
prevent
reinfect
import
analyz
whether
absolut
control
exist
correl
protect
hiv
field
clearli
shown
small
fraction
infect
individu
develop
broadli
neutral
antibodi
control
viral
mutant
develop
infect
prevent
progress
diseas
case
hcmv
interest
determin
whether
product
antibodi
individu
antigen
domain
gb
matter
addit
envelop
glycoprotein
correl
reduc
suscept
reinfect
note
gb
protein
region
harbor
highli
conserv
differ
hcmv
isol
fig
situat
well
outsid
polymorph
protein
segment
defin
summari
investig
human
antibodi
repertoir
gb
use
recombin
protein
current
use
vaccin
trial
data
reveal
new
antigen
site
protein
immunogen
infect
importantli
target
potent
antivir
antibodi
interest
compar
find
bcell
repertoir
gb
produc
infect
sinc
may
enabl
us
draw
conclus
structur
integr
gb
vaccin
antigen
improv
understand
antigen
map
gb
valu
ration
design
futur
vaccin
antigen
lastli
human
mab
potent
broadli
neutral
activ
might
use
biolog
prophylaxi
andor
therapi
hcmv
infect
ethic
approv
sampl
collect
obtain
ethic
committe
medic
faculti
friedrichalexand
written
inform
consent
obtain
donor
african
green
monkey
kidney
cell
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
germani
supplement
fetal
calf
serum
fc
glutamin
mgl
gentamicin
mgl
hcmv
propag
human
fetal
lung
fibroblast
human
foreskin
fibroblast
hff
grown
dmem
supplement
fc
glutamin
gentamicin
immunofluoresc
cell
grown
glass
coverslip
plate
repres
recombin
hcmv
express
firefli
luciferas
gene
control
hcmv
promot
peripher
blood
mononuclear
cell
pbmc
isol
peripher
blood
healthi
hcmvposit
volunt
use
ficolldens
gradient
centrifug
bcell
enrich
use
antihuman
mitenyi
biotec
bergisch
gladbach
germani
b
cell
label
follow
reagent
antihuman
dianova
germani
antihuman
bd
bioscienc
pharmigen
switzerland
antihuman
iggfitc
dianova
germani
glycoprotein
b
sanofi
pasteur
ng
per
b
cell
gb
protein
label
use
fluorolinkab
label
kit
amersham
pharmacia
biotech
germani
gbspecif
iggposit
memori
b
cell
either
analyz
use
facscalibur
becton
dickinson
germani
isol
sort
cell
fulfil
criteria
percppefitc
cell
sort
cellswel
fbottom
micropl
contain
confluent
layer
irradi
feeder
cell
hff
use
moflo
cell
sorter
cytom
germani
sort
cell
grown
complet
medium
supplement
mm
glutamin
iuml
penicillin
mgml
streptomycin
mm
fc
heatinactiv
panbiotech
germani
presenc
ebv
cpg
odn
previous
describ
week
cultur
supernat
screen
antigen
recognit
viru
neutral
supernat
classifi
neutral
dilut
neutral
capac
exceed
input
viru
produc
select
recombin
human
monoclon
antibodi
ig
heavi
correspond
light
chain
amplifi
rtpcr
clonal
expand
activ
memori
b
cell
clone
eukaryot
express
vector
exactli
describ
tiller
et
al
respect
clone
vector
kindli
provid
h
wardemann
berlin
v
gene
usag
cdr
sequenc
suppli
tabl
fibroblast
volum
ml
seed
plate
pfu
preincub
serial
log
dilut
complement
inactiv
serum
mab
volum
ml
cultur
medium
h
mixtur
ad
fibroblast
h
inoculum
remov
cell
incub
h
cell
lyse
use
ml
glo
lysi
buffer
promega
usa
per
well
ml
cell
lysat
place
white
liaplat
per
well
ml
assay
buffer
mm
kh
po
mm
glycylglycin
mgso
egta
mm
atp
mm
dtt
ad
luciferas
activ
measur
inject
ml
dluciferin
pjk
germani
solut
per
well
mm
glycylglycin
mgso
egta
mm
dtt
mm
dluciferin
detect
chemiluminesc
perform
orion
micropl
luminomet
berthold
technolog
germani
neutral
assay
use
endotheli
epitheli
cell
perform
use
hcmv
isol
describ
influenc
complement
neutral
capac
monoclon
antibodi
test
inclus
rabbit
complement
cedarlan
lab
canada
neutral
assay
fibroblast
seed
cell
per
well
plate
preincub
individu
mab
h
concentr
ensur
complet
neutral
cell
virusmab
mixtur
cool
virusmab
mixtur
ad
cell
multipl
infect
moi
follow
incub
cell
wash
three
time
icecold
pb
cell
lysat
prepar
freezingthaw
dna
extract
lysat
use
magna
pure
lc
roch
germani
instrument
quantit
realtim
pcr
perform
abi
prism
control
recoveri
cell
copi
number
albumin
dna
determin
parallel
hcmv
hcmv
copi
calcul
per
copi
albumin
primer
cmv
gagcagactctcagaggatcgg
cmv
aagcggcctctgataaccaag
albumin
gtgaacaggcgaccatgct
albumin
gcatggaaggtgaatgtttcag
penetr
assay
precool
cell
preincub
viru
moi
h
wash
twice
icecold
pb
incub
h
log
dilut
mab
incub
remain
mab
remov
wash
twice
pb
cell
incub
h
subsequ
step
carri
accord
viru
neutral
assay
chemiluminesc
viru
set
construct
express
plasmid
code
complet
gb
describ
previous
carboxytermin
truncat
form
gb
express
use
plasmid
aminotermin
truncat
express
use
vector
base
plasmid
contain
code
sequenc
hcmv
authent
signal
sequenc
aa
follow
code
sequenc
influenza
hemagglutinin
ha
epitop
ypydvpdya
express
dom
ii
nucleotid
sequenc
code
aa
chemic
synthes
geneart
germani
two
part
join
nucleotid
linker
code
sequenc
ilealaglysergli
insert
give
rise
express
dom
nucleotid
sequenc
code
aa
insert
gener
plasmid
express
glutathionstransferas
fusion
protein
e
coli
use
express
vector
pharmacia
biotech
germani
cell
grown
glass
coverslip
plate
transfect
mg
plasmid
dna
use
lipofectamin
invitrogen
germani
hour
transfect
cell
fix
permeabil
ice
cold
methanol
primari
antibodi
ad
unbound
primari
antibodi
remov
three
wash
step
use
pb
bind
primari
antibodi
detect
appropri
secondari
antibodi
conjug
fitc
fluorescein
isothiocyan
dako
germani
counterstain
cell
nuclei
done
dapi
imag
collect
use
zeiss
axioplan
fluoresc
microscop
fit
visitron
system
chargecoupl
devic
camera
puchheim
germani
imag
process
use
metaview
softwar
adob
photoshop
antibodi
gbspecif
human
mab
gnspecif
murin
mab
ghspecif
murin
mab
murin
antiha
sigma
aldrich
germani
murin
antigst
biozol
germani
plasmid
dna
use
transform
e
coli
express
gst
fusion
protein
respect
fusion
protein
induc
solubl
form
protein
purifi
e
coli
lysat
accord
manufactur
instruct
prepar
affin
matrix
mg
purifi
fusion
protein
dialys
coupl
buffer
conjug
aminolink
plu
coupl
resin
thermo
fisher
scientif
usa
accord
manufactur
instruct
four
ml
hcmv
hyperimmun
globulin
prepar
dilut
vv
pb
pass
ml
antigencoupl
bead
follow
extens
wash
pb
bound
igg
elut
glycinhcl
ph
ml
fraction
fraction
dialys
pb
total
igg
concentr
determin
elisa
brief
polystyren
plate
coat
ng
affinipur
goat
antihuman
igg
fccspecif
jackson
immuno
research
usa
carbon
buffer
ph
overnight
serial
log
dilut
elut
fraction
volum
ml
ad
bound
igg
detect
use
polyclon
peroxidaseconjug
goat
f
ab
fragment
antihuman
igg
fccspecif
jackson
immuno
research
usa
human
igg
prepar
jackson
immuno
research
usa
known
concentr
use
standard
follow
gbspecif
antigen
use
gb
contain
aa
gb
contain
aa
protein
dilut
ng
ng
depend
antigen
sodium
carbon
buffer
ph
urea
ml
use
coat
microtit
plate
overnight
subsequ
step
carri
room
temperatur
reaction
well
rins
pb
supplement
tween
block
h
pb
contain
fc
plate
rins
pb
supplement
tween
incub
mab
human
serum
polyclon
elut
antibodi
fraction
mlwell
h
unbound
antibodi
remov
wash
peroxidaseconjug
antihuman
antimous
igg
dako
germani
ad
appropri
dilut
h
plate
wash
ml
tmb
tetramethylbenzidin
peroxidas
substrat
dilut
peroxidas
substrat
solut
b
kpl
usa
ad
min
reaction
stop
addit
ml
h
po
od
determin
use
emax
micropl
reader
eurofin
mwg
operon
germani
dilut
antibodi
done
pb
fc
assay
involv
gb
fusion
protein
respect
prokaryot
fusion
partner
assay
parallel
optic
densiti
subtract
valu
obtain
gb
fusion
protein
antibodi
human
sera
measur
captur
elisa
well
plate
coat
ngwell
antiha
monoclon
antibodi
sigma
germani
block
h
pb
contain
fc
plate
incub
cultur
supernat
cell
transfect
six
day
plate
rins
incub
human
sera
dilut
h
plate
wash
develop
describ
model
hcmv
gb
structur
gener
standard
homolog
model
procedur
use
program
model
base
sequenc
align
templat
structur
gb
two
loop
region
val
glu
leu
hcmv
gb
resolv
refer
structur
could
therefor
model
imag
gener
accelri
ds
visual
qualiti
model
valid
use
prosa
procheck
prosa
analysi
reveal
overal
model
qualiti
zscore
quit
similar
templat
crystal
structur
zscore
valu
within
rang
zscore
typic
found
crystal
structur
protein
similar
size
addit
residu
energi
profil
templat
target
structur
similar
indic
model
place
amino
acid
unfavour
environ
addit
analysi
backbon
geometri
show
residu
hcmv
gb
locat
favour
region
ramachandran
plot
valu
correspond
crystal
structur
resolut
hcmv
gb
model
made
avail
author
upon
request
genbank
access
number
individu
heavi
light
chain
nucleotid
sequenc
recombinantli
express
igg
molecul
protein
express
purifi
describ
materi
method
b
kinet
data
bind
gb
dom
iigst
use
fabfrag
gener
papain
digest
kinet
experi
perform
use
biacor
ge
healthcar
germani
gb
dom
iigst
protein
captur
seri
sensor
chip
ge
healthcar
germani
use
nhydroxysuccinimidenethylndimethylaminopropylcarboimid
chemistri
pb
use
run
buffer
approxim
ru
dom
iigst
gst
refer
surfac
captur
contact
time
sec
flow
rate
mlmin
differ
concentr
nm
inject
contact
time
sec
dissoci
time
sec
flow
rate
mlmin
sensor
surfac
regener
bind
reaction
mm
glycin
ph
contact
time
sec
flow
rate
mlmin
kinet
fit
bind
model
k
appar
associ
rate
constant
k
appar
dissoci
rate
constant
k
appar
dissoci
equilibrium
c
circular
dichroism
cd
measur
dom
ii
protein
demonstr
structur
fold
presciss
proteas
ge
healthcar
germani
use
cleav
gsttag
dom
ii
protein
concentr
mm
dialyz
mm
sodium
phosphat
buffer
ph
filtrat
cd
measur
perform
use
jasco
cd
spectromet
jasco
japan
cuvett
cm
path
length
spectrum
regist
nm
correct
contribut
phosphat
buffer
spectrum
accumul
eight
time
band
width
nm
sensit
mdeg
scan
speed
nmmin
time
respons
sec
data
pitch
nm
tif
figur
qualiti
control
dom
iispecif
polyclon
antibodi
prepar
affin
purifi
polyclon
antibodi
fraction
specif
dom
ii
gb
elisa
plate
coat
gb
dom
ii
respect
test
variou
antibodi
dom
ii
poli
affin
purifi
igg
fraction
serum
pool
pre
serum
pool
affin
purif
serum
post
serum
pool
affin
purif
mab
mab
antigst
murin
mab
specif
gst
b
affin
purifi
polyclon
antibodi
fraction
contain
detect
antibodi
addit
envelop
glycoprotein
hcmv
cell
transfect
plasmid
indic
top
row
h
later
cell
fix
incub
affin
purifi
igg
fraction
upper
panel
control
antibodi
lower
panel
bind
primari
antibodi
detect
incub
appropri
fitcconjug
secondari
antibodi
antiha
mous
mab
specif
ha
human
mab
mous
mab
specif
gmgn
complex
mous
mab
specif
gh
antibodi
purif
perform
twice
similar
result
tif
figur
sequenc
align
hcmv
strain
clinic
isol
full
length
hcmv
protein
sequenc
genbank
embl
databas
access
number
left
align
hcmv
strain
region
domain
domain
ii
well
depict
two
region
hypervari
lie
close
nterminu
ctermin
domain
ii
linker
region
protein
align
perform
geneiou
softwar
